Have a feature idea you'd love to see implemented? Let us know!

GALT Galectin Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: GALT

Price (delayed)

$2.55

Market cap

$158.81M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.79

Enterprise value

$226.63M

Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug belapectin (formerly known as GR-MD-02) is a ...

Highlights
GALT's equity has dropped by 59% year-on-year and by 15% since the previous quarter
The debt has soared by 55% YoY and by 13% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.galectintherapeutics.com
Peers: MEIP MNKD MNOV NERV

Key stats

What are the main financial stats of GALT
Market
Shares outstanding
62.28M
Market cap
$158.81M
Enterprise value
$226.63M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$43.9M
EBITDA
-$43.87M
Free cash flow
-$32.78M
Per share
EPS
-$0.79
Free cash flow per share
-$0.53
Book value per share
-$1.35
Revenue per share
$0
TBVPS
$0.44
Balance sheet
Total assets
$27.66M
Total liabilities
$109.8M
Debt
$93.42M
Equity
-$83.87M
Working capital
$12.67M
Liquidity
Debt to equity
-1.11
Current ratio
1.87
Quick ratio
1.75
Net debt/EBITDA
-1.55
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-184.9%
Return on equity
N/A
Return on invested capital
-66.5%
Return on capital employed
-336.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GALT stock price

How has the Galectin Therapeutics stock price performed over time
Intraday
-1.16%
1 week
-4.14%
1 month
-4.49%
1 year
23.19%
YTD
53.61%
QTD
-7.27%

Financial performance

How have Galectin Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$39.67M
Net income
-$47.9M
Gross margin
N/A
Net margin
N/A
The company's net income fell by 20% YoY and by 7% QoQ
The operating income has declined by 6% since the previous quarter and by 4.1% year-on-year

Growth

What is Galectin Therapeutics's growth rate over time

Valuation

What is Galectin Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Galectin Therapeutics's EPS has decreased by 20% YoY and by 7% QoQ
GALT's equity has dropped by 59% year-on-year and by 15% since the previous quarter

Efficiency

How efficient is Galectin Therapeutics business performance
GALT's ROIC is up by 37% YoY and by 5% QoQ
The ROA has grown by 8% YoY

Dividends

What is GALT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GALT.

Financial health

How did Galectin Therapeutics financials performed over time
Galectin Therapeutics's total assets is 75% less than its total liabilities
The total liabilities has soared by 54% YoY and by 13% from the previous quarter
Galectin Therapeutics's total assets has increased by 38% YoY and by 7% from the previous quarter
GALT's equity has dropped by 59% year-on-year and by 15% since the previous quarter
The debt has soared by 55% YoY and by 13% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.